New molecular avenues in Parkinson's disease therapy

Current Topics in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 913-948

  Di Napoli, Mario ^a,b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b SMDN Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention   (Italy)

Author keywords

synuclein; Autophagy; DJ 1; Dopaminergic neurons; Genetics; Leucine rich repeat kinase 2 (LRRK2); Lewy bodies; Oxidative stress; Parkin; Parkinson's disease; Pink1 (PTEN induced kinase 1); Translational medicine; Ubiquitin proteasome system; UCH L1 (ubiquitin carboxyterminal hydrolase L1)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CELL PROTEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MANEB; PARAQUAT; PARKIN; PROTEASOME; PROTEIN SYNPHILIN 1; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE LOCUS; HUMAN; MOLECULAR GENETICS; MOLECULAR THERAPY; MOTOR DYSFUNCTION; NERVE INJURY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; HUMANS; PARKINSON DISEASE;

EID: 74249097494     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789378254     Document Type: Review

References (295)

1. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68, 384-386.
2. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004, 61, 561-566.
3. Di Napoli, M.; Shah, I.M.; Stewart, D.A. Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev. Neurother. 2007, 7, 1693-1729.
4. Olanow, C.W.; Kieburtz, K.; Schapira, A.H. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann. Neurol. 2008, 64, (Suppl. 2), S101-S110.
5. Braak, H.; Bohl, J.R.; Muller, C.M.; Rub, U.; de Vos, R.A.; Del Tredici, K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21, 2042-2051.
6. Wolters, E.C.; Braak, H. Parkinson's disease: premotor clinicopathological correlations. J. Neural. Transm. Suppl. 2006, (70), 309-319.
7. Poewe, W.H.; Wenning, G.K. The natural history of Parkinson's disease. Ann. Neurol. 1998, 44, S1-S9.
8. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980.
9. Jeon, B.S.; Jackson-Lewis, V.; Burke, R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995, 4, 131-137.
10. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3, 1301-1306.
11. Campbell, B.C.; McLean, C.A.; Culvenor, J.G.; Gai, W.P.; Blumbergs, P.C.; Jakala, P.; Beyreuther, K.; Masters, C.L.; Li, Q.X. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 2001, 76, 87-96.
12. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318, 121-134.
13. Beyer, K.; Domingo-Sabat, M.; Ariza, A. Molecular pathology of lewy body diseases. Int. J. Mol. Sci. 2009, 10, 724-745.
14. McNaught, K.S.; Olanow, C.W.; Halliwell, B.; Isacson, O.; Jenner, P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2001, 2, 589-594.
15. McNaught, K.S.; Jackson, T.; JnoBaptiste, R.; Kapustin, A.; Olanow, C.W. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006, 66, S37-S49.
16. Brundin, P.; Li, J.Y.; Holton, J.L.; Lindvall, O.; Revesz, T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9, 741-745.
17. Kordower, J.H.; Chu, Y.; Hauser, R.A.; Freeman, T.B.; Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14, 504-506.
18. Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.; Bjorklund, A.; Widner, H.; Revesz, T.; Lindvall, O.; Brundin, P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest hostto-graft disease propagation. Nat. Med. 2008, 14, 501-503.
19. Gorman, A.M. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell Mol. Med. 2008, 12, 2263-2280.
20. Sommer, D.B.; Stacy, M.A. What's in the pipeline for the treatment of Parkinson's disease? Expert Rev. Neurother. 2008, 8, 1829-1839.
21. Case, A.; Stein, R.L. Kinetic analysis of the action of tissue transglutaminase on peptide and protein substrates. Biochemistry 2003, 42, 9466-9481.
22. Konno, T.; Morii, T.; Hirata, A.; Sato, S.; Oiki, S.; Ikura, K. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 2005, 44, 2072-2079.
23. NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 2008, 31, 141-150.
24. Elmer, L.W.; Bertoni, J.M. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. Expert Opin. Pharmacother. 2008, 9, 2759-2772.
25. Olanow, C.W.; Hauser, R.A.; Jankovic, J.; Langston, W.; Lang, A.; Poewe, W.; Tolosa, E.; Stocchi, F.; Melamed, E.; Eyal, E.; Rascol, O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 2008, 23, 2194-2201.
26. The NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007, 68, 20-28.
27. Outeiro, T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317, 516-519.
28. Sauve, A.A.; Wolberger, C.; Schramm, V.L.; Boeke, J.D. The biochemistry of sirtuins. Ann. Rev. Biochem. 2006, 75, 435-465.
29. Kanthasamy, A.G.; Anantharam, V.; Zhang, D.; Latchoumycandane, C.; Jin, H.; Kaul, S.; Kanthasamy, A. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic. Biol. Med. 2006, 41, 1578-1589.
30. Cookson, M.R. The biochemistry of Parkinson's disease. Ann. Rev. Biochem. 2005, 74, 29-52.
31. Maries, E.; Dass, B.; Collier, T.J.; Kordower, J.H.; Steece-Collier, K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 2003, 4, 727-738.
32. Dawson, T.M.; Dawson, V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 2003, 111, 145-151.
33. Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; Llorens, V.; Gomez, T.E.; del Ser, T.; Munoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164-173.
34. Duda, J.E.; Giasson, B.I.; Mabon, M.E.; Miller, D.C.; Golbe, L.I.; Lee, V.M.; Trojanowski, J.Q. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002, 104, 7-11.
35. Yamaguchi, K.; Cochran, E.J.; Murrell, J.R.; Polymeropoulos, M.H.; Shannon, K.M.; Crowther, R.A.; Goedert, M.; Ghetti, B. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alphasynuclein gene. Acta Neuropathol. 2005, 110, 298-305.
36. Markopoulou, K.; Dickson, D.W.; McComb, R.D.; Wszolek, Z.K.; Katechalidou, L.; Avery, L.; Stansbury, M.S.; Chase, B.A. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathol. 2008, 116, 25-35.
37. Chartier-Harlin, M.C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; Waucquier, N.; Defebvre, L.; Amouyel, P.; Farrer, M.; Destee, A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364, 1167-1169.
38. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302, 841.
39. Fuchs, J.; Nilsson, C.; Kachergus, J.; Munz, M.; Larsson, E.M.; Schule, B.; Langston, J.W.; Middleton, F.A.; Ross, O.A.; Hulihan, M.; Gasser, T.; Farrer, M.J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68, 916-922.
40. Miller, D.W.; Hague, S.M.; Clarimon, J.; Baptista, M.; Gwinn-Hardy, K.; Cookson, M.R.; Singleton, A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62, 1835-1838.
41. El Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Curran, M.D.; Gibson, M.J.; Court JA; Schlossmacher, M.G.; Allsop, D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20, 419-425.
42. Johnson, J.; Hague, S.M.; Hanson, M.; Gibson, A.; Wilson, K.E.; Evans, E.W.; Singleton, A.A.; McInerney-Leo, A.; Nussbaum, R.L.; Hernandez, D.G.; Gallardo, M.; McKeith, I.G.; Burn, D.J.; Ryu, M.; Hellstrom, O.; Ravina, B.; Eerola, J.; Perry, R.H.; Jaros, E.; Tienari, P.; Weiser, R.; Gwinn-Hardy, K.; Morris, C.M.; Hardy, J.; Singleton, A.B. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004, 63, 554-556.
43. Pals, P.; Lincoln, S.; Manning, J.; Heckman, M.; Skipper, L.; Hulihan, M.; Van den, B.M.; De Pooter, T.; Cras, P.; Crook, J.; Van Broeckhoven, C.; Farrer, M.J. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56, 591-595.
44. Maraganore, D.M.; de Andrade, M.; Elbaz, A.; Farrer, M.J.; Ioannidis, J.P.; Kruger, R.; Rocca, W.A.; Schneider, N.K.; Lesnick, T.G.; Lincoln, S.J.; Hulihan, M.M.; Aasly, J.O.; Ashizawa, T.; Chartier-Harlin, M.C.; Checkoway, H.; Ferrarese, C.; Hadjigeorgiou, G.; Hattori, N.; Kawakami, H.; Lambert, J.C.; Lynch, T.; Mellick, G.D.; Papapetropoulos, S.; Parsian, A.; Quattrone, A.; Riess, O.; Tan, E.K.; Van Broeckhoven, C. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296, 661-670.
45. George, J.M. The synucleins. Genome Biol. 2002, 3, REVIEWS3002.
46. Ferreon, A.C.; Deniz, A.A. alpha-Synuclein Multistate Folding Thermodynamics: Implications for Protein Misfolding and Aggregation. Biochemistry 2007, 46, 4499-4509.
47. Martinez, Z.; Zhu, M.; Han, S.; Fink, A.L. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46, 1868-1877.
48. Cole, N.B.; Murphy, D.D. The cell biology of alpha-synuclein: a sticky problem? Neuromol. Med. 2002, 1, 95-109.
49. Outeiro, T.F.; Lindquist, S. Yeast cells provide insight into alphasynuclein biology and pathobiology. Science 2003, 302, 1772-1775.
50. Fortin, D.L.; Nemani, V.M.; Voglmaier, S.M.; Anthony, M.D.; Ryan, T.A.; Edwards, R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 2005, 25, 10913-10921.
51. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W.H.; Castillo, P.E.; Shinsky, N.; Verdugo, J.M.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D.; Rosenthal, A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25, 239-252.
52. Cabin, D.E.; Shimazu, K.; Murphy, D.; Cole, N.B.; Gottschalk, W.; McIlwain, K.L.; Orrison, B.; Chen, A.; Ellis, C.E.; Paylor, R.; Lu, B.; Nussbaum, R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22, 8797-8807.
53. Steidl, J.V.; Gomez-Isla, T.; Mariash, A.; Ashe, K.H.; Boland, L.M. Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice. Neuroreport 2003, 14, 219-223.
54. Martin, E.D.; Gonzalez-Garcia, C.; Milan, M.; Farinas, I.; Cena, V. Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. Eur. J. Neurosci. 2004, 20, 3085-3091.
55. Liu, S.; Ninan, I.; Antonova, I.; Battaglia, F.; Trinchese, F.; Narasanna, A.; Kolodilov, N.; Dauer, W.; Hawkins, R.D.; Arancio, O. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 2004, 23, 4506-4516.
56. Larsen, K.E.; Schmitz, Y.; Troyer, M.D.; Mosharov, E.; Dietrich, P.; Quazi, A.Z.; Savalle, M.; Nemani, V.; Chaudhry, F.A.; Edwards, R.H.; Stefanis, L.; Sulzer, D. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26, 11915-11922.
57. Gitler, A.D.; Bevis, B.J.; Shorter, J.; Strathearn, K.E.; Hamamichi, S.; Su, L.J.; Caldwell, K.A.; Caldwell, G.A.; Rochet, J.C.; McCaffery, J.M.; Barlowe, C.; Lindquist, S. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105, 145-150.
58. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22, 3090-3099.
59. Chandra, S.; Fornai, F.; Kwon, H.B.; Yazdani, U.; Atasoy, D.; Liu, X.; Hammer, R.E.; Battaglia, G.; German, D.C.; Castillo, P.E.; Sudhof, T.C. Double-knockout mice for alpha- and betasynucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. USA 2004, 101, 14966-14971.
60. Drolet, R.E.; Behrouz, B.; Lookingland, K.J.; Goudreau, J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004, 25, 761-769.
61. Lotharius, J.; Brundin, P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3, 932-942.
62. Giasson, B.I.; Duda, J.E.; Quinn, S.M.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alphasynuclein. Neuron 2002, 34, 521-533.
63. Lee, M.K.; Stirling, W.; Xu, Y.; Xu, X.; Qui, D.; Mandir, A.S.; Dawson, T.M.; Copeland, N.G.; Jenkins, N.A.; Price, D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alphasynuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 8968-8973.
64. Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science 2000, 287, 1265-1269.
65. Richfield, E.K.; Thiruchelvam, M.J.; Cory-Slechta, D.A.; Wuertzer, C.; Gainetdinov, R.R.; Caron, M.G.; Di Monte, D.A.; Federoff, H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 2002, 175, 35-48.
66. Maingay, M.; Romero-Ramos, M.; Kirik, D. Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS. Spectr. 2005, 10, 235-244.
67. Mochizuki, H.; Yamada, M.; Mizuno, Y. Alpha-synuclein overexpression model. J. Neural. Transm. Suppl. 2006, 281-284.
68. Eslamboli, A.; Romero-Ramos, M.; Burger, C.; Bjorklund, T.; Muzyczka, N.; Mandel, R.J.; Baker, H.; Ridley, R.M.; Kirik, D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130, 799-815.
69. Purisai, M.G.; McCormack, A.L.; Langston, W.J.; Johnston, L.C.; Di Monte, D.A. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 2005, 20, 898-906.
70. Manning-Bog, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277, 1641-1644.
71. Vila, M.; Vukosavic, S.; Jackson-Lewis, V.; Neystat, M.; Jakowec, M.; Przedborski, S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74, 721-729.
72. Gomez-Santos, C.; Ferrer, I.; Reiriz, J.; Vinals, F.; Barrachina, M.; Ambrosio, S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SHSY5Y cells. Brain. Res. 2002, 935, 32-39.
73. Chandra, S.; Gallardo, G.; Fernandez-Chacon, R.; Schluter, O.M.; Sudhof, T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123, 383-396.
74. Bonini, N.M.; Giasson, B.I. Snaring the function of alphasynuclein. Cell 2005, 123, 359-361.
75. Malsam, J.; Kreye, S.; Sollner, T.H. Membrane fusion: SNAREs and regulation. Cell Mol. Life Sci. 2008, 65, 2814-2832.
76. Fernandez-Chacon, R.; Wolfel, M.; Nishimune, H.; Tabares, L.; Schmitz, F.; Castellano-Munoz, M.; Rosenmund, C.; Montesinos, M.L.; Sanes, J.R.; Schneggenburger, R.; Sudhof, T.C. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 2004, 42, 237-251.
77. Sung, J.Y.; Lee, H.J.; Jeong, E.I.; Oh, Y.; Park, J.; Kang, K.S.; Chung, K.C. alpha-Synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells. Neurosci. Lett. 2007, 416, 289-293.
78. Sidhu, A.; Wersinger, C.; Moussa, C.E.; Vernier, P. The Role of {alpha}-Synuclein in Both Neuroprotection and Neurodegeneration. Ann. NY Acad. Sci. 2004, 1035, 250-270.
79. Andersen, J.K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 2004, 10(Suppl.), S18-S25.
80. Ahlskog, J.E. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov. Disord. 2005, 20, 271-282.
81. Orth, M.; Tabrizi, S.J. Models of Parkinson's disease. Mov. Disord. 2003, 18, 729-737.
82. Rott, R.; Szargel, R.; Haskin, J.; Shani, V.; Shainskaya, A.; Manov, I.; Liani, E.; Avraham, E.; Engelender, S. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 2008, 283, 3316-3328.
83. Lee, J.T.; Wheeler, T.C.; Li, L.; Chin, L.S. Ubiquitination of alphasynuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet. 2008, 17, 906-917.
84. Cappai, R.; Leck, S.L.; Tew, D.J.; Williamson, N.A.; Smith, D.P.; Galatis, D.; Sharples, R.A.; Curtain, C.C.; Ali, F.E.; Cherny, R.A.; Culvenor, J.G.; Bottomley, S.P.; Masters, C.L.; Barnham, K.J.; Hill, A.F. Dopamine promotes & alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005, 19, 1377-1379.
85. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418, 291.
86. Pountney, D.L.; Lowe, R.; Quilty, M.; Vickers, J.C.; Voelcker, N.H.; Gai, W.P. Annular alpha-synuclein species from purified multiple system atrophy inclusions. J. Neurochem. 2004, 90, 502-512.
87. Tsigelny, I.F.; Bar-On, P.; Sharikov, Y.; Crews, L.; Hashimoto, M.; Miller, M.A.; Keller, S.H.; Platoshyn, O.; Yuan, J.X.; Masliah, E. Dynamics of alpha-synuclein aggregation and inhibition of porelike oligomer development by beta-synuclein. FEBS J. 2007, 274, 1862-1877.
88. Lee, S.J. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J. Mol. Neurosci. 2008, 34, 17-22.
89. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160-164.
90. Chen, L.; Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8, 657-663.
91. Arawaka, S.; Wada, M.; Goto, S.; Karube, H.; Sakamoto, M.; Ren, C.H.; Koyama, S.; Nagasawa, H.; Kimura, H.; Kawanami, T.; Kurita, K.; Tajima, K.; Daimon, M.; Baba, M.; Kido, T.; Saino, S.; Goto, K.; Asao, H.; Kitanaka, C.; Takashita, E.; Hongo, S.; Nakamura, T.; Kayama, T.; Suzuki, Y.; Kobayashi, K.; Katagiri, T.; Kurokawa, K.; Kurimura, M.; Toyoshima, I.; Niizato, K.; Tsuchiya, K.; Iwatsubo, T.; Muramatsu, M.; Matsumine, H.; Kato, T. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci. 2006, 26, 9227-9238.
92. Takahashi, M.; Uchikado, H.; Caprotti, D.; Weidenheim, K.M.; Dickson, D.W.; Ksiezak-Reding, H.; Pasinetti, G.M. Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 2006, 65, 1157-1169.
93. Inglis, K.J.; Chereau, D.; Brigham, E.F.; Chiou, S.S.; Schobel, S.; Frigon, N.L.; Yu, M.; Caccavello, R.J.; Nelson, S.; Motter, R.; Wright, S.; Chian, D.; Santiago, P.; Soriano, F.; Ramos, C.; Powell, K.; Goldstein, J.M.; Babcock, M.; Yednock, T.; Bard, F.; Basi, G.S.; Sham, H.; Chilcote, T.J.; McConlogue, L.; Griswold-Prenner, I.; Anderson, J.P. Polo-like kinase 2 (PLK2) phosphorylates alphasynuclein at serine 129 in central nervous system. J. Biol. Chem. 2009, 284, 2598-2602.
94. Seeburg, D.P.; Feliu-Mojer, M.; Gaiottino, J.; Pak, D.T.; Sheng, M. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron 2008, 58, 571-583.
95. Hoyer, W.; Cherny, D.; Subramaniam, V.; Jovin, T.M. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 2004, 43, 16233-16242.
96. Li, W.; West, N.; Colla, E.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, T.M.; Jakala, P.; Hartmann, T.; Price, D.L.; Lee, M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA 2005, 102, 2162-2167.
97. Liu, C.W.; Giasson, B.I.; Lewis, K.A.; Lee, V.M.; DeMartino, G.N.; Thomas, P.J. A precipitating role for truncated alphasynuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 2005, 280, 22670-22678.
98. Tofaris, G.K.; Garcia, R.P.; Humby, T.; Lambourne, S.L.; O'Connell, M.; Ghetti, B.; Gossage, H.; Emson, P.C.; Wilkinson, L.S.; Goedert, M.; Spillantini, M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120) : implications for Lewy body disorders. J. Neurosci. 2006, 26, 3942-3950.
99. Paxinou, E.; Chen, Q.; Weisse, M.; Giasson, B.I.; Norris, E.H.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M.; Ischiropoulos, H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 2001, 21, 8053-8061.
100. Cuervo, A.M.; Stefanis, L.; Fredenburg, R.; Lansbury, P.T.; Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004, 305, 1292-1295.
101. Dufty, B.M.; Warner, L.R.; Hou, S.T.; Jiang, S.X.; Gomez-Isla, T.; Leenhouts, K.M.; Oxford, J.T.; Feany, M.B.; Masliah, E.; Rohn, T.T. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 2007, 170, 1725-1738.
102. Kim, H.J.; Lee, D.; Lee, C.H.; Chung, K.C.; Kim, J.; Paik, S.R. Calpain-resistant fragment(s) of alpha-synuclein regulates the synuclein-cleaving activity of 20S proteasome. Arch. Biochem. Biophys. 2006, 455, 40-47.
103. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions. Science 2000, 290, 985-989.
104. Duda, J.E.; Giasson, B.I.; Chen, Q.; Gur, T.L.; Hurtig, H.I.; Stern, M.B.; Gollomp, S.M.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 2000, 157, 1439-1445.
105. Hodara, R.; Norris, E.H.; Giasson, B.I.; Mishizen-Eberz, A.J.; Lynch, D.R.; Lee, V.M.; Ischiropoulos, H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 2004, 279, 47746-47753.
106. Uversky, V.N.; Yamin, G.; Munishkina, L.A.; Karymov, M.A.; Millett, I.S.; Doniach, S.; Lyubchenko, Y.L.; Fink, A.L. Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res. Mol. Brain Res. 2005, 134, 84-102.
107. Mishizen-Eberz, A.J.; Norris, E.H.; Giasson, B.I.; Hodara, R.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q.; Lynch, D.R. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005, 44, 7818-7829.
108. Chen, Q.; Thorpe, J.; Keller, J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 2005, 280, 30009-30017.
109. Chen, L.; Thiruchelvam, M.J.; Madura, K.; Richfield, E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis. 2006, 23, 120-126.
110. Kruger, R. The role of synphilin-1 in synaptic function and protein degradation. Cell Tissue Res. 2004, 318, 195-199.
111. Szargel, R.; Rott, R.; Engelender, S. Synphilin-1 isoforms in Parkinson's disease: regulation by phosphorylation and ubiquitylation. Cell Mol. Life Sci. 2008, 65, 80-88.
112. Avraham, E.; Szargel, R.; Eyal, A.; Rott, R.; Engelender, S. Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J. Biol. Chem. 2005, 280, 42877-42886.
113. Lim, K.L.; Chew, K.C.; Tan, J.M.; Wang, C.; Chung, K.K.; Zhang, Y.; Tanaka, Y.; Smith, W.; Engelender, S.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 2005, 25, 2002-2009.
114. Szargel, R.; Rott, R.; Eyal, A.; Haskin, J.; Shani, V.; Balan, L.; Wolosker, H.; Engelender, S. Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation. J. Biol. Chem. 2009, 284, 10706-11716.
115. Ito, T.; Niwa, J.; Hishikawa, N.; Ishigaki, S.; Doyu, M.; Sobue, G. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J. Biol. Chem. 2003, 278, 29106-29114.
116. Marx, F.P.; Soehn, A.S.; Berg, D.; Melle, C.; Schiesling, C.; Lang, M.; Kautzmann, S.; Strauss, K.M.; Franck, T.; Engelender, S.; Pahnke, J.; Dawson, S.; von Eggeling, F.; Schulz, J.B.; Riess, O.; Kruger, R. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein - implications for Parkinson's disease. FASEB J. 2007, 21, 1759-1767.
117. Wolf, D.H.; Hilt, W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim. Biophys. Acta 2004, 1695, 19-31.
118. Adams, J. The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 2003, 29, (Suppl.) 1, 3-9.
119. Pines, J.; Lindon, C. Proteolysis: anytime, any place, anywhere? Nat. Cell Biol. 2005, 7, 731-735.
120. Sherman, M.Y.; Goldberg, A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29, 15-32. [121] Sawada, H.; Kohno, R.; Kihara, T.; Izumi, Y.; Sakka, N.; Ibi, M.; Nakanishi, M.; Nakamizo, T.; Yamakawa, K.; Shibasaki, H.; Yamamoto, N.; Akaike, A.; Inden, M.; Kitamura, Y.; Taniguchi, T.; Shimohama, S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 2004, 279, 10710-10719.
121. Schapira, A.H.; Cleeter, M.W.; Muddle, J.R.; Workman, J.M.; Cooper, J.M.; King, R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 2006, 60, 253-255.
122. McNaught, K.S.; Bjorklund, L.M.; Belizaire, R.; Isacson, O.; Jenner, P.; Olanow, C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002, 13, 1437-1441.
123. Fornai, F.; Lenzi, P.; Gesi, M.; Ferrucci, M.; Lazzeri, G.; Busceti, C.L.; Ruffoli, R.; Soldani, P.; Ruggieri, S.; Alessandri, M.G.; Paparelli, A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 2003, 23, 8955-8966.
124. McNaught, K.S.; Perl, D.P.; Brownell, A.L.; Olanow, C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56, 149-162.
125. Miwa, H.; Kubo, T.; Suzuki, A.; Nishi, K.; Kondo, T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 2005, 380, 93-98.
126. Zhang, X.; Xie, W.; Qu, S.; Pan, T.; Wang, X.; Le, W. Neuroprotection by iron chelator against proteasome inhibitorinduced nigral degeneration. Biochem. Biophys. Res. Commun. 2005, 333, 544-549.
127. Zeng, B.Y.; Bukhatwa, S.; Hikima, A.; Rose, S.; Jenner, P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 2006, 60, 248-252.
128. Bove, J.; Zhou, C.; Jackson-Lewis, V.; Taylor, J.; Chu, Y.; Rideout, H.J.; Wu, D.C.; Kordower, J.H.; Petrucelli, L.; Przedborski, S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 2006, 60, 260-264.
129. McNaught, K.S.; Olanow, C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 2006, 60, 243-247.
130. Kordower, J.H.; Kanaan, N.M.; Chu, Y.; Suresh, B.R.; Stansell, J., III; Terpstra, B.T.; Sortwell, C.E.; Steece-Collier, K.; Collier, T.J. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 2006, 60, 264-268.
131. Nair, V.D.; McNaught, K.S.; Gonzalez-Maeso, J.; Sealfon, S.C.; Olanow, C.W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 2006, 281, 39550-39560.
132. Sun, F.; Anantharam, V.; Zhang, D.; Latchoumycandane, C.; Kanthasamy, A.; Kanthasamy, A.G. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 2006, 27, 807-815.
133. Manning-Bog, A.B.; Reaney, S.H.; Chou, V.P.; Johnston, L.C.; McCormack, A.L.; Johnston, J.; Langston, J.W.; Di Monte, D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 2006, 60, 256-260.
134. Hawlitschka, A.; Haas, S.J.; Schmitt, O.; Weiss, D.G.; Wree, A. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 2007, 1173, 137-144.
135. Mathur, B.N.; Neely, M.D.; Dyllick-Brenzinger, M.; Tandon, A.; Deutch, A.Y. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007, 1168, 83-89.
136. Landau, A.M.; Kouassi, E.; Siegrist-Johnstone, R.; Desbarats, J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov. Disord. 2007, 22, 403-407.
137. Kadoguchi, N.; Kimoto, H.; Yano, R.; Kato, H.; Araki, T. Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice. Metab. Brain Dis. 2008, 23, 147-154.
138. Reaney, S.H.; Johnston, L.C.; Langston, W.J.; Di Monte, D.A. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp. Neurol. 2006, 202, 434-440.
139. Dekker, M.C.; Bonifati, V.; van Duijn, C.M. Parkinson's disease: piecing together a genetic jigsaw. Brain 2003, 126, 1722-1733.
140. Lohmann, E.; Periquet, M.; Bonifati, V.; Wood, N.W.; De Michele, G.; Bonnet, A.M.; Fraix, V.; Broussolle, E.; Horstink, M.W.; Vidailhet, M.; Verpillat, P.; Gasser, T.; Nicholl, D.; Teive, H.; Raskin, S.; Rascol, O.; Destee, A.; Ruberg, M.; Gasparini, F.; Meco, G.; Agid, Y.; Durr, A.; Brice, A.; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 2003, 54, 176-185.
141. Oliveira, S.A.; Scott, W.K.; Nance, M.A.; Watts, R.L.; Hubble, J.P.; Koller, W.C.; Lyons, K.E.; Pahwa, R.; Stern, M.B.; Hiner, B.C.; Jankovic, J.; Ondo, W.G.; Allen, F.H., Jr.; Scott, B.L.; Goetz, C.G.; Small, G.W.; Mastaglia, F.L.; Stajich, J.M.; Zhang, F.; Booze, M.W.; Reaves, J.A.; Middleton, L.T.; Haines, J.L.; Pericak-Vance, M.A.; Vance, J.M.; Martin, E.R. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch. Neurol. 2003, 60, 975-980.
142. Scott, W.K.; Nance, M.A.; Watts, R.L.; Hubble, J.P.; Koller, W.C.; Lyons, K.; Pahwa, R.; Stern, M.B.; Colcher, A.; Hiner, B.C.; Jankovic, J.; Ondo, W.G.; Allen, F.H., Jr.; Goetz, C.G.; Small, G.W.; Masterman, D.; Mastaglia, F.; Laing, N.G.; Stajich, J.M.; Slotterbeck, B.; Booze, M.W.; Ribble, R.C.; Rampersaud, E.; West, S.G.; Gibson, R.A.; Middleton, L.T.; Roses, A.D.; Haines, J.L.; Scott, B.L.; Vance, J.M.; Pericak-Vance, M.A. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001, 286, 2239-2244.
143. Ghione, I.; Di Fonzo, A.; Saladino, F.; Del Bo, R.; Bresolin, N.; Comi, G.P.; Rango, M. Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. Neurotoxicology 2007, 28, 698-701.
144. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25, 302-305.
145. Sakata, E.; Yamaguchi, Y.; Kurimoto, E.; Kikuchi, J.; Yokoyama, S.; Yamada, S.; Kawahara, H.; Yokosawa, H.; Hattori, N.; Mizuno, Y.; Tanaka, K.; Kato, K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 2003, 4, 301-306.
146. Farrer, M.; Chan, P.; Chen, R.; Tan, L.; Lincoln, S.; Hernandez, D.; Forno, L.; Gwinn-Hardy, K.; Petrucelli, L.; Hussey, J.; Singleton, A.; Tanner, C.; Hardy, J.; Langston, J.W. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 2001, 50, 293-300.
147. Dawson, T.M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural. Transm. Suppl. 2006, 209-213.
148. Wang, C.; Ko, H.S.; Thomas, B.; Tsang, F.; Chew, K.C.; Tay, S.P.; Ho, M.W.; Lim, T.M.; Soong, T.W.; Pletnikova, O.; Troncoso, J.; Dawson, V.L.; Dawson, T.M.; Lim, K.L. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 2005, 14, 3885-3897.
149. Hampe, C.; Ardila-Osorio, H.; Fournier, M.; Brice, A.; Corti, O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 2006, 15, 2059-2075.
150. Wong, E.S.; Tan, J.M.; Wang, C.; Zhang, Z.; Tay, S.P.; Zaiden, N.; Ko, H.S.; Dawson, V.L.; Dawson, T.M.; Lim, K.L. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. 2007, 282, 12310-12318.
151. Zhang, Y.; Gao, J.; Chung, K.K.; Huang, H.; Dawson, V.L.; Dawson, T.M. Parkin functions as an E2-dependent ubiquitinprotein ligase and promotes the degradation of the synaptic vesicleassociated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 2000, 97, 13354-13359.
152. Imai, Y.; Soda, M.; Inoue, H.; Hattori, N.; Mizuno, Y.; Takahashi, R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001, 105, 891-902.
153. Shimura, H.; Schlossmacher, M.G.; Hattori, N.; Frosch, M.P.; Trockenbacher, A.; Schneider, R.; Mizuno, Y.; Kosik, K.S.; Selkoe, D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293, 263-269.
154. Chung, K.K.; Zhang, Y.; Lim, K.L.; Tanaka, Y.; Huang, H.; Gao, J.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkin ubiquitinates the alpha-synuclein- interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 2001, 7, 1144-1150.
155. Staropoli, J.F.; McDermott, C.; Martinat, C.; Schulman, B.; Demireva, E.; Abeliovich, A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37, 735-749.
156. Ren, Y.; Zhao, J.; Feng, J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 2003, 23, 3316-3324.
157. Tsai, Y.C.; Fishman, P.S.; Thakor, N.V.; Oyler, G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278, 22044-22055.
158. Corti, O.; Hampe, C.; Koutnikova, H.; Darios, F.; Jacquier, S.; Prigent, A.; Robinson, J.C.; Pradier, L.; Ruberg, M.; Mirande, M.; Hirsch, E.; Rooney, T.; Fournier, A.; Brice, A. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 2003, 12, 1427-1437.
159. Ko, H.S.; Kim, S.W.; Sriram, S.R.; Dawson, V.L.; Dawson, T.M. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem. 2006, 281, 16193-16196.
160. Feng, J. Genetic Factors in Parkinson's Disease and Potential Therapeutic Targets. Curr. Neuropharm. 2003, 1, 301-313.
161. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; Zhang, J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19, 533-542.
162. Ren, Y.; Jiang, H.; Yang, F.; Nakaso, K.; Feng, J. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J. Biol. Chem. 2009, 284, 4009-4017.
163. Jiang, H.; Jiang, Q.; Feng, J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J. Biol. Chem. 2004, 279, 54380-54386.
164. Huynh, D.P.; Scoles, D.R.; Nguyen, D.; Pulst, S.M. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 2003, 12, 2587-2597.
165. Hampton, R.Y. ER-associated degradation in protein quality control and cellular regulation. Curr. Opin. Cell Biol. 2002, 14, 476-482.
166. Tsai, B.; Ye, Y.; Rapoport, T.A. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat. Rev. Mol. Cell Biol. 2002, 3, 246-255.
167. Yang, F.; Jiang, Q.; Zhao, J.; Ren, Y.; Sutton, M.D.; Feng, J. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J. Biol. Chem. 2005, 280, 17154-17162.
168. Imai, Y.; Soda, M.; Murakami, T.; Shoji, M.; Abe, K.; Takahashi, R. A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J. Biol. Chem. 2003, 278, 51901-51910.
169. Zhao, J.; Ren, Y.; Jiang, Q.; Feng, J. Parkin is recruited to the centrosome in response to inhibition of proteasomes. J. Cell Sci. 2003, 116, 4011-4019.
170. Jiang, H.; Jiang, Q.; Liu, W.; Feng, J. Parkin suppresses the expression of monoamine oxidases. J. Biol. Chem. 2006, 281, 8591-8599.
171. Ren, Y.; Liu, W.; Jiang, H.; Jiang, Q.; Feng, J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 2005, 280, 34105-34112.
172. Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279, 18614-18622.
173. Periquet, M.; Corti, O.; Jacquier, S.; Brice, A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 2005, 95, 1259-1276.
174. Nikolaev, A.Y.; Li, M.; Puskas, N.; Qin, J.; Gu, W. Parc: a cytoplasmic anchor for p53. Cell 2003, 112, 29-40.
175. Giannakakou, P.; Sackett, D.L.; Ward, Y.; Webster, K.R.; Blagosklonny, M.V.; Fojo, T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2000, 2, 709-717.
176. O'Brate, A.; Giannakakou, P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug. Resist. Update 2003, 6, 313-322.
177. Kalia, S.K.; Lee, S.; Smith, P.D.; Liu, L.; Crocker, S.J.; Thorarinsdottir, T.E.; Glover, J.R.; Fon, E.A.; Park, D.S.; Lozano, A.M. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004, 44, 931-945.
178. Fallon, L.; Moreau, F.; Croft, B.G.; Labib, N.; Gu, W.J.; Fon, E.A. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J. Biol. Chem. 2002, 277, 486-491.
179. Fallon, L.; Belanger, C.M.; Corera, A.T.; Kontogiannea, M.; Regan-Klapisz, E.; Moreau, F.; Voortman, J.; Haber, M.; Rouleau, G.; Thorarinsdottir, T.; Brice, A.; van Bergen En Henegouwen PM; Fon, E.A. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 2006, 8, 834-842.
180. Henn, I.H.; Bouman, L.; Schlehe, J.S.; Schlierf, A.; Schramm, J.E.; Wegener, E.; Nakaso, K.; Culmsee, C.; Berninger, B.; Krappmann, D.; Tatzelt, J.; Winklhofer, K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 2007, 27, 1868-1878.
181. Oliveira, S.A.; Li, Y.J.; Noureddine, M.A.; Zuchner, S.; Qin, X.; Pericak-Vance, M.A.; Vance, J.M. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am. J. Hum. Genet. 2005, 77, 252-264.
182. Liu, Y.; Fallon, L.; Lashuel, H.A.; Liu, Z.; Lansbury, P.T., Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111, 209-218.
183. Levecque, C.; Destee, A.; Mouroux, V.; Becquet, E.; Defebvre, L.; Amouyel, P.; Chartier-Harlin, M.C. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural. Transm. 2001, 108, 979-984.
184. Satoh, J.; Kuroda, Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 2001, 189, 113-117.
185. Nishikawa, K.; Li, H.; Kawamura, R.; Osaka, H.; Wang, Y.L.; Hara, Y.; Hirokawa, T.; Manago, Y.; Amano, T.; Noda, M.; Aoki, S.; Wada, K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 2003, 304, 176-183.
186. Moore, D.J.; Zhang, L.; Troncoso, J.; Lee, M.K.; Hattori, N.; Mizuno, Y.; Dawson, T.M.; Dawson, V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 2005, 14, 71-84.
187. Chung, K.K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, V.L.; Dawson, T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304, 1328-1331.
188. Avraham, E.; Rott, R.; Liani, E.; Szargel, R.; Engelender, S. Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J. Biol. Chem. 2007, 282, 12842-12850.
189. Smith, P.D.; Mount, M.P.; Shree, R.; Callaghan, S.; Slack, R.S.; Anisman, H.; Vincent, I.; Wang, X.; Mao, Z.; Park, D.S. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 2006, 26, 440-447.
190. Smith, P.D.; Crocker, S.J.; Jackson-Lewis, V.; Jordan-Sciutto, K.L.; Hayley, S.; Mount, M.P.; O'Hare, M.J.; Callaghan, S.; Slack, R.S.; Przedborski, S.; Anisman, H.; Park, D.S. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2003, 100, 13650-13655.
191. LaVoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11, 1214-1221.
192. McNaught, K.S.; Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 2001, 297, 191-194.
193. McNaught, K.S.; Belizaire, R.; Isacson, O.; Jenner, P.; Olanow, C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 2003, 179, 38-46.
194. Massey, A.C.; Zhang, C.; Cuervo, A.M. Chaperone-mediated autophagy in aging and disease. Curr. Top. Dev. Biol. 2006, 73, 205-235.
195. Menzies, F.M.; Ravikumar, B.; Rubinsztein, D.C. Protective roles for induction of autophagy in multiple proteinopathies. Autophagy 2006, 2, 224-225.
196. Rubinsztein, D.C.; DiFiglia, M.; Heintz, N.; Nixon, R.A.; Qin, Z.H.; Ravikumar, B.; Stefanis, L.; Tolkovsky, A. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005, 1, 11-22.
197. Stefanis, L.; Larsen, K.E.; Rideout, H.J.; Sulzer, D.; Greene, L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21, 9549-9560.
198. Bandhyopadhyay, U.; Cuervo, A.M. Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from alpha-synuclein. Exp. Gerontol. 2007, 42, 120-128.
199. Webb, J.L.; Ravikumar, B.; Atkins, J.; Skepper, J.N.; Rubinsztein, D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278, 25009-25013.
200. Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; Yokoyama, M.; Mishima, K.; Saito, I.; Okano, H.; Mizushima, N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441, 885-889.
201. Komatsu, M.; Waguri, S.; Chiba, T.; Murata, S.; Iwata, J.; Tanida, I.; Ueno, T.; Koike, M.; Uchiyama, Y.; Kominami, E.; Tanaka, K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441, 880-884.
202. Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; Taylor, R.W.; Turnbull, D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38, 515-517.
203. Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38, 518-520.
204. Davidzon, G.; Greene, P.; Mancuso, M.; Klos, K.J.; Ahlskog, J.E.; Hirano, M.; DiMauro, S. Early-onset familial parkinsonism due to POLG mutations. Ann. Neurol. 2006, 59, 859-862.
205. Bolton, J.L.; Trush, M.A.; Penning, T.M.; Dryhurst, G.; Monks, T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 2000, 13, 135-160.
206. Cohen, G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. NY Acad. Sci. 2000, 899, 112-120.
207. Shults, C.W. Mitochondrial dysfunction and possible treatments in Parkinson's disease - a review. Mitochondrion 2004, 4, 641-648.
208. Bonifati, V.; Rizzu, P.; Squitieri, F.; Krieger, E.; Vanacore, N.; van Swieten, J.C.; Brice, A.; van Duijn, C.M.; Oostra, B.; Meco, G.; Heutink, P. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 2003, 24, 159-160.
209. Kubo, S.; Hattori, N.; Mizuno, Y. Recessive Parkinson's disease. Mov. Disord. 2006, 21, 885-893.
210. Bonifati, V.; Rizzu, P.; van Baren, M.J.; Schaap, O.; Breedveld, G.J.; Krieger, E.; Dekker, M.C.; Squitieri, F.; Ibanez, P.; Joosse, M.; van Dongen, J.W.; Vanacore, N.; van Swieten, J.C.; Brice, A.; Meco, G.; van Duijn, C.M.; Oostra, B.A.; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256-259.
211. Bandopadhyay, R.; Kingsbury, A.E.; Cookson, M.R.; Reid, A.R.; Evans, I.M.; Hope, A.D.; Pittman, A.M.; Lashley, T.; Canet-Aviles, R.; Miller, D.W.; McLendon, C.; Strand, C.; Leonard, A.J.; Abou-Sleiman, P.M.; Healy, D.G.; Ariga, H.; Wood, N.W.; de Silva, R.; Revesz, T.; Hardy, J.A.; Lees, A.J. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004, 127, 420-430.
212. Olzmann, J.A.; Brown, K.; Wilkinson, K.D.; Rees, H.D.; Huai, Q.; Ke, H.; Levey, A.I.; Li, L.; Chin, L.S. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J. Biol. Chem. 2004, 279, 8506-8515.
213. Canet-Aviles, R.M.; Wilson, M.A.; Miller, D.W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S.; Baptista, M.J.; Ringe, D.; Petsko, G.A.; Cookson, M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 2004, 101, 9103-9108.
214. Kinumi, T.; Kimata, J.; Taira, T.; Ariga, H.; Niki, E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2004, 317, 722-728.
215. Yokota, T.; Sugawara, K.; Ito, K.; Takahashi, R.; Ariga, H.; Mizusawa, H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 2003, 312, 1342-1348.
216. Yang, Y.; Gehrke, S.; Haque, M.E.; Imai, Y.; Kosek, J.; Yang, L.; Beal, M.F.; Nishimura, I.; Wakamatsu, K.; Ito, S.; Takahashi, R.; Lu, B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. USA 2005, 102, 13670-13675.
217. Meulener, M.; Whitworth, A.J.; Armstrong-Gold, C.E.; Rizzu, P.; Heutink, P.; Wes, P.D.; Pallanck, L.J.; Bonini, N.M. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 2005, 15, 1572-1577.
218. Park, J.; Kim, S.Y.; Cha, G.H.; Lee, S.B.; Kim, S.; Chung, J. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 2005, 361, 133-139.
219. Cookson, M.R.; Xiromerisiou, G.; Singleton, A. How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr. Opin. Neurol. 2005, 18, 706-711.
220. Zhou, W.; Zhu, M.; Wilson, M.A.; Petsko, G.A.; Fink, A.L. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol. 2006, 356, 1036-1048.
221. Kim, R.H.; Smith, P.D.; Aleyasin, H.; Hayley, S.; Mount, M.P.; Pownall, S.; Wakeham, A.; You, T.; Kalia, S.K.; Horne, P.; Westaway, D.; Lozano, A.M.; Anisman, H.; Park, D.S.; Mak, T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA 2005, 102, 5215-5220.
222. Ito, G.; Ariga, H.; Nakagawa, Y.; Iwatsubo, T. Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. Biochem. Biophys. Res. Commun. 2006, 339, 667-672.
223. Abou-Sleiman, P.M.; Muqit, M.M.; Wood, N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7, 207-219.
224. Valente, E.M.; Bentivoglio, A.R.; Dixon, P.H.; Ferraris, A.; Ialongo, T.; Frontali, M.; Albanese, A.; Wood, N.W. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 2001, 68, 895-900.
225. Tan, J.M.; Dawson, T.M. Parkin blushed by PINK1. Neuron 2006, 50, 527-529.
226. Valente, E.M.; Abou-Sleiman, P.M.; Caputo, V.; Muqit, M.M.; Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A.R.; Healy, D.G.; Albanese, A.; Nussbaum, R.; Gonzalez-Maldonado, R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W.P.; Latchman, D.S.; Harvey, R.J.; Dallapiccola, B.; Auburger, G.; Wood, N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304, 1158-1160.
227. Muqit, M.M.; Abou-Sleiman, P.M.; Saurin, A.T.; Harvey, K.; Gandhi, S.; Deas, E.; Eaton, S.; Payne, S.; Venner, K.; Matilla, A.; Healy, D.G.; Gilks, W.P.; Lees, A.J.; Holton, J.; Revesz, T.; Parker, P.J.; Harvey, R.J.; Wood, N.W.; Latchman, D.S. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem. 2006, 98, 156-169.
228. Park, J.; Lee, S.B.; Lee, S.; Kim, Y.; Song, S.; Kim, S.; Bae, E.; Kim, J.; Shong, M.; Kim, J.M.; Chung, J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441, 1157-1161.
229. Yang, Y.; Gehrke, S.; Imai, Y.; Huang, Z.; Ouyang, Y.; Wang, J.W.; Yang, L.; Beal, M.F.; Vogel, H.; Lu, B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA 2006, 103, 10793-10798.
230. Eura, Y.; Ishihara, N.; Yokota, S.; Mihara, K. Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J. Biochem. 2003, 134, 333-344.
231. Misaka, T.; Miyashita, T.; Kubo, Y. Primary structure of a dynamin-related mouse mitochondrial GTPase and its distribution in brain, subcellular localization, and effect on mitochondrial morphology. J. Biol. Chem. 2002, 277, 15834-15842.
232. James, D.I.; Parone, P.A.; Mattenberger, Y.; Martinou, J.C. hFis1, a novel component of the mammalian mitochondrial fission machinery. J. Biol. Chem. 2003, 278, 36373-36379.
233. Poole, A.C.; Thomas, R.E.; Andrews, L.A.; McBride, H.M.; Whitworth, A.J.; Pallanck, L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 2008, 105, 1638-1643.
234. Wang, D.; Qian, L.; Xiong, H.; Liu, J.; Neckameyer, W.S.; Oldham, S.; Xia, K.; Wang, J.; Bodmer, R.; Zhang, Z. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. USA 2006, 103, 13520-13525.
235. Strauss, K.M.; Martins, L.M.; Plun-Favreau, H.; Marx, F.P.; Kautzmann, S.; Berg, D.; Gasser, T.; Wszolek, Z.; Muller, T.; Bornemann, A.; Wolburg, H.; Downward, J.; Riess, O.; Schulz, J.B.; Kruger, R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 2005, 14, 2099-2111.
236. Faccio, L.; Fusco, C.; Viel, A.; Zervos, A.S. Tissue-specific splicing of Omi stress-regulated endoprotease leads to an inactive protease with a modified PDZ motif. Genomics 2000, 68, 343-347. [238] Li, W.; Srinivasula, S.M.; Chai, J.; Li, P.; Wu, J.W.; Zhang, Z.; Alnemri, E.S.; Shi, Y. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat. Struct. Biol. 2002, 9, 436-441.
237. Verhagen, A.M.; Silke, J.; Ekert, P.G.; Pakusch, M.; Kaufmann, H.; Connolly, L.M.; Day, C.L.; Tikoo, A.; Burke, R.; Wrobel, C.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 2002, 277, 445-454.
238. Martins, L.M.; Iaccarino, I.; Tenev, T.; Gschmeissner, S.; Totty, N.F.; Lemoine, N.R.; Savopoulos, J.; Gray, C.W.; Creasy, C.L.; Dingwall, C.; Downward, J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. 2002, 277, 439-444.
239. Jones, J.M.; Datta, P.; Srinivasula, S.M.; Ji, W.; Gupta, S.; Zhang, Z.; Davies, E.; Hajnoczky, G.; Saunders, T.L.; Van Keuren, M.L.; Fernandes-Alnemri, T.; Meisler, M.H.; Alnemri, E.S. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003, 425, 721-727.
240. Martins, L.M.; Morrison, A.; Klupsch, K.; Fedele, V.; Moisoi, N.; Teismann, P.; Abuin, A.; Grau, E.; Geppert, M.; Livi, G.P.; Creasy, C.L.; Martin, A.; Hargreaves, I.; Heales, S.J.; Okada, H.; Brandner, S.; Schulz, J.B.; Mak, T.; Downward, J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell Biol. 2004, 24, 9848-9862.
241. Schapira, A.H. Mitochondrial disease. Lancet 2006, 368, 70-82.
242. Funayama, M.; Hasegawa, K.; Ohta, E.; Kawashima, N.; Komiyama, M.; Kowa, H.; Tsuji, S.; Obata, F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 2005, 57, 918-921.
243. Whaley, N.R.; Uitti, R.J.; Dickson, D.W.; Farrer, M.J.; Wszolek, Z.K. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J. Neural. Transm. Suppl. 2006, 221-229.
244. Galter, D.; Westerlund, M.; Carmine, A.; Lindqvist, E.; Sydow, O.; Olson, L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 2006, 59, 714-719.
245. Taymans, J.M.; Van den, H.C.; Baekelandt, V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 2006, 98, 951-961.
246. Miklossy, J.; Arai, T.; Guo, J.P.; Klegeris, A.; Yu, S.; McGeer, E.G.; McGeer, P.L. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006, 65, 953-963.
247. West, A.B.; Moore, D.J.; Biskup, S.; Bugayenko, A.; Smith, W.W.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 2005, 102, 16842-16847.
248. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M.P.; Beilina, A.; Blackinton, J.; Thomas, K.J.; Ahmad, R.; Miller, D.W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R.J.; Harvey, K.; Cookson, M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23, 329-341.
249. Gloeckner, C.J.; Kinkl, N.; Schumacher, A.; Braun, R.J.; O'Neill, E.; Meitinger, T.; Kolch, W.; Prokisch, H.; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 2006, 15, 223-232.
250. MacLeod, D.; Dowman, J.; Hammond, R.; Leete, T.; Inoue, K.; Abeliovich, A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52, 587-593.
251. Hatano, T.; Kubo, S.; Imai, S.; Maeda, M.; Ishikawa, K.; Mizuno, Y.; Hattori, N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007, 16, 678-690.
252. Mata, I.F.; Wedemeyer, W.J.; Farrer, M.J.; Taylor, J.P.; Gallo, K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29, 286-293.
253. Paisan-Ruiz, C.; Jain, S.; Evans, E.W.; Gilks, W.P.; Simon, J.; van der, B.M.; Lopez, d.M.; Aparicio, S.; Gil, A.M.; Khan, N.; Johnson, J.; Martinez, J.R.; Nicholl, D.; Carrera, I.M.; Pena, A.S.; de Silva, R.; Lees, A.; Marti-Masso, J.F.; Perez-Tur, J.; Wood, N.W.; Singleton, A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44, 595-600.
254. Ito, G.; Okai, T.; Fujino, G.; Takeda, K.; Ichijo, H.; Katada, T.; Iwatsubo, T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007, 46, 1380-1388.
255. Smith, W.W.; Pei, Z.; Jiang, H.; Moore, D.J.; Liang, Y.; West, A.B.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA 2005, 102, 18676-18681.
256. Toft, M.; Mata, I.F.; Kachergus, J.M.; Ross, O.A.; Farrer, M.J. LRRK2 mutations and Parkinsonism. Lancet 2005, 365, 1229-1230.
257. Marin, I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 2006, 23, 2423-2433.
258. Guo, L.; Gandhi, P.N.; Wang, W.; Petersen, R.B.; Wilson-Delfosse, A.L.; Chen, S.G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 2007, 313, 3658-3670.
259. Lewis, P.A.; Greggio, E.; Beilina, A.; Jain, S.; Baker, A.; Cookson, M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 2007, 357, 668-671.
260. West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; Dawson, T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16, 223-232.
261. Li, C.; Beal, M.F. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. Proc. Natl. Acad. Sci. USA 2005, 102, 16535-16536.
262. Burke, R.E. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther. 2007, 114, 261-277.
263. White, L.R.; Toft, M.; Kvam, S.N.; Farrer, M.J.; Aasly, J.O. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res. 2007, 85, 1288-1294.
264. Habig, K.; Walter, M.; Poths, S.; Riess, O.; Bonin, M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 2008, 9, 83-94.
265. Jaleel, M.; Nichols, R.J.; Deak, M.; Campbell, D.G.; Gillardon, F.; Knebel, A.; Alessi, D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405, 307-317.
266. Biskup, S.; Moore, D.J.; Celsi, F.; Higashi, S.; West, A.B.; Andrabi, S.A.; Kurkinen, K.; Yu, S.W.; Savitt, J.M.; Waldvogel, H.J.; Faull, R.L.; Emson, P.C.; Torp, R.; Ottersen, O.P.; Dawson, T.M.; Dawson, V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60, 557-569.
267. Melrose, H.L.; Kent, C.B.; Taylor, J.P.; Dachsel, J.C.; Hinkle, K.M.; Lincoln, S.J.; Mok, S.S.; Culvenor, J.G.; Masters, C.L.; Tyndall, G.M.; Bass, D.I.; Ahmed, Z.; Andorfer, C.A.; Ross, O.A.; Wszolek, Z.K.; Delldonne, A.; Dickson, D.W.; Farrer, M.J. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147, 1047-1058.
268. Schapira, A.H. The importance of LRRK2 mutations in Parkinson disease. Arch. Neurol. 2006, 63, 1225-1228.
269. Zhou, H.; Falkenburger, B.H.; Schulz, J.B.; Tieu, K.; Xu, Z.; Xia, X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int. J. Biol. Sci. 2007, 3, 242-250.
270. Li, Y.; Liu, W.; Oo, T.F.; Wang, L.; Tang, Y.; Jackson-Lewis, V.; Zhou, C.; Geghman, K.; Bogdanov, M.; Przedborski, S.; Beal, M.F.; Burke, R.E.; Li, C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12, 826-828.
271. Rajput, A.; Dickson, D.W.; Robinson, C.A.; Ross, O.A.; Dachsel, J.C.; Lincoln, S.J.; Cobb, S.A.; Rajput, M.L.; Farrer, M.J. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67, 1506-1508.
272. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R.J.; Calne, D.B.; Stoessl, A.J.; Pfeiffer, R.F.; Patenge, N.; Carbajal, I.C.; Vieregge, P.; Asmus, F.; Muller-Myhsok, B.; Dickson, D.W.; Meitinger, T.; Strom, T.M.; Wszolek, Z.K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44, 601-607.
273. Farrer, M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 2006, 7, 306-318.
274. Yamada, M.; Mizuno, Y.; Mochizuki, H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 2005, 16, 262-270.
275. Dachsel, J.C.; Lincoln, S.J.; Gonzalez, J.; Ross, O.A.; Dickson, D.W.; Farrer, M.J. The ups and downs of alpha-synuclein mRNA expression. Mov. Disord. 2007, 22, 293-295.
276. Sapru, M.K.; Yates, J.W.; Hogan, S.; Jiang, L.; Halter, J.; Bohn, M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 2006, 198, 382-390.
277. Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; Games, D.; Schenk, D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46, 857-868.
278. Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 2008, 283, 23542-23556.
279. Beyer, K.; Ariza, A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr. Med. Chem. 2008, 15, 2748-2759.
280. Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.; Iwatsubo, T.; Hisanaga, S.; Goedert, M.; Hasegawa, M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 2006, 45, 6085-6094.
281. Schmidt, M.L.; Schuck, T.; Sheridan, S.; Kung, M.P.; Kung, H.; Zhuang, Z.P.; Bergeron, C.; Lamarche, J.S.; Skovronsky, D.; Giasson, B.I.; Lee, V.M.; Trojanowski, J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am. J. Pathol. 2001, 159, 937-943.
282. Abe, K.; Kobayashi, N.; Sode, K.; Ikebukuro, K. Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning. BMC Bioinformatics 2007, 8, 451.
283. Bodles, A.M.; Guthrie, D.J.; Greer, B.; Irvine, G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 2001, 78, 384-395.
284. Bodles, A.M.; El Agnaf, O.M.; Greer, B.; Guthrie, D.J.; Irvine, G.B. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci. Lett. 2004, 359, 89-93. [287] El Agnaf, O.M.; Paleologou, K.E.; Greer, B.; Abogrein, A.M.; King, J.E.; Salem, S.A.; Fullwood, N.J.; Benson, F.E.; Hewitt, R.; Ford, K.J.; Martin, F.L.; Harriott, P.; Cookson, M.R.; Allsop, D. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 2004, 18, 1315-1317.
285. El Agnaf, O.M.; Jakes, R.; Curran, M.D.; Middleton, D.; Ingenito, R.; Bianchi, E.; Pessi, A.; Neill, D.; Wallace, A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998, 440, 71-75.
286. El Agnaf, O.M.; Irvine, G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 2002, 30, 559-565.
287. El Agnaf, O.M.; Irvine, G.B. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 2000, 130, 300-309.
288. Paleologou, K.E.; Irvine, G.B.; El Agnaf, O.M. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans. 2005, 33, 1106-1110.
289. Brody, K.M.; Taylor, J.M.; Wilson, G.R.; Delatycki, M.B.; Lockhart, P.J. Regional and cellular localisation of Parkin coregulated gene in developing and adult mouse brain. Brain Res. 2008, 1201, 177-186.
290. Dawe, H.R.; Farr, H.; Portman, N.; Shaw, M.K.; Gull, K. The Parkin co-regulated gene product, PACRG, is an evolutionarily conserved axonemal protein that functions in outer-doublet microtubule morphogenesis. J. Cell Sci. 2005, 118, 5421-5430.
291. Lockhart, P.J.; O'Farrell, C.A.; Farrer, M.J. It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG). Mov. Disord. 2004, 19, 101-104.
292. Nalepa, G.; Rolfe, M.; Harper, J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5, 596-613.
293. Ahn, M.; Kim, S.; Kang, M.; Ryu, Y.; Kim, T.D. Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases. Biochem. Biophys. Res. Commun. 2006, 346, 1142-1149.
294. Winklhofer, K.F.; Tatzelt, J. The role of chaperones in Parkinson's disease and prion diseases. Handb. Exp. Pharmacol. 2006, 221-258.
295. Gregersen, N. Protein misfolding disorders: pathogenesis and intervention. J. Inherit. Metab. Dis. 2006, 29, 456-470.